Denali Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
| Denali Therapeutics Inc. | |
|---|---|
| Index to Consolidated Financial Statements | |
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 147 |
| Consolidated Balance Sheets | 149 |
| Consolidated Statements of Operations and Comprehensive Loss | 150 |
| Consolidated Statements of Stockholders' Equity | 151 |
| Consolidated Statements of Cash Flows | 152 |
| Notes to Consolidated Financial Statements | 153 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.